重性抑郁障碍患者五羟色胺转运体基因多态性与抗抑郁治疗相关分析

Association between genetic polymorphism of 5-hydroxytryptamine transporter and effect of antidepressive treatment in patients with major depressive disorders

目的:探讨重性抑郁障碍患者五羟色胺转运体(5-HTT)基因第2内含子区可变数目串联重复序列多态性(5-HTTVNTR)与抗抑郁治疗临床疗效及不良反应的相关性。方法:研究对象为重性抑郁障碍患者82例,给予抗抑郁药物氟西汀治疗,采用HAMD抑郁量表及TESS副作用量表评定疗效及不良反应。利用聚合酶链反应(PCR)技术检测5-HTT基因VNTR多态性,进行基因型分析。结果:药物治疗有效组和无效组之间5-HTTVNTR等位基因频率和基因型无统计学差异;有副作用组和无副作用组之间基因型和等位基因频率的差异有统计学意义。结论:5-HTTVNTR基因多态性可能是重性抑郁障碍患者氟西汀药物治疗副作用(恶心)的遗传影响因子。

Objective To investigate the relationship between genetic polymorphism of 5-hydroxytryptamine transporter （5-HTT） intron 2 variable number tandem repeat （VNTR） and clinical response, adverse reaction of anti-depressive treatment in patients with major depressive disorders. Methods The effect and adverse reaction in 82 patients with major depressive disorder who were treated with fluoxetine were measured by HAMD scale and TESS scale respectively. And the genetic polymorphism and genotype of 5-HTTVNTR was determined by polymerase chain reaction-based technique. Results There were no significant differences of genotype and allelic distribution of 5-HTTVNTR between effective group and ineffective group, but there were significantly differences between adverse reaction group and non-adverse reaction group. Conclusion The genetic polymorphism of 5- HTTVNTR may be associated with the adverse reaction of fluoxetine in treating patients with major depressive disorders.